Press releases.

Press releases 2019

Press releases 2019
December 18th 2019

INSIGHT-004 Clinical Trial Update

November 13th 2019

Immutep Announces European Patent Grant for LAG525 Antibody

November 7th 2019

Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC

November 1st 2019

IMMUTEP AGM 2019 - Chairman's Address

November 1st 2019

IMMUTEP AGM 2019 - CEO Marc Voigt's CEO Presentation

November 1st 2019

Update - Consolidation Split - IMM

October 28th 2019

Operational Update

October 15th 2019

Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

October 10th 2019

Immutep Announces Data Presentations at Upcoming Industry Conferences

October 10th 2019

Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

September 26th 2019

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

September 23rd 2019

Immutep to Receive £4M Milestone Payment from GSK

September 17th 2019

Immutep Announces Japanese Patent Grant for LAG525 Antibody

August 22nd 2019

Immutep Granted European Patent for Eftilagimod Alpha in Cancer

August 6th 2019

Immutep Completes A$6M Entitlement Offer

July 29th 2019

Operational Update

June 25th 2019

Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer

June 21st 2019

Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy

June 13th 2019

Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial

June 6th 2019

INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”

June 3rd 2019

Immutep Presentation at ASCO 2019

May 23rd 2019

Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy

May 17th 2019

Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

May 10th 2019

Immutep Announces Upcoming Industry Conference Participation

April 30th 2019

Operational Update

March 27th 2019

Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast

March 25th 2019

Presentation related to webcast 25. March 2019 - Immutep to Present IMP761 Preclinical Results

March 21st 2019

Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer

March 18th 2019

Immutep to Present IMP761 Preclinical Results in Global Webcast

March 7th 2019

Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation

March 7th 2019

Immutep receives A$872,351 R&D Tax Incentive

March 6th 2019

Immutep doses First Patient in TACTI-002 Phase II Trial

March 5th 2019

Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

March 4th 2019

Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference

February 26th 2019

Immutep to Present at Upcoming Industry Conferences

January 7th 2019

Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic